Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor

  • Takuya Toyonaga
  • Shigeru Yamaguchi
  • Kenji Hirata
  • Kentaro Kobayashi
  • Osamu Manabe
  • Shiro Watanabe
  • Shunsuke Terasaka
  • Hiroyuki Kobayashi
  • Naoya Hattori
  • Tohru Shiga
  • Yuji Kuge
  • Shinya Tanaka
  • Yoichi M. Ito
  • Nagara Tamaki
Original Article

Abstract

Purpose

Metabolic activity and hypoxia are both important factors characterizing tumor aggressiveness. Here, we used F-18 fluoromisonidazole (FMISO) and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) to define metabolically active hypoxic volume, and investigate its clinical significance in relation to progression free survival (PFS) and overall survival (OS) in glioblastoma patients.

Experimental Design

Glioblastoma patients (n = 32) underwent FMISO PET, FDG PET, and magnetic resonance imaging (MRI) before surgical intervention. FDG and FMISO PET images were coregistered with gadolinium-enhanced T1-weighted MR images. Volume of interest (VOI) of gross tumor volume (GTV) was manually created to enclose the entire gadolinium-positive areas. The FMISO tumor-to-normal region ratio (TNR) and FDG TNR were calculated in a voxel-by-voxel manner. For calculating TNR, standardized uptake value (SUV) was divided by averaged SUV of normal references. Contralateral frontal and parietal cortices were used as the reference region for FDG, whereas the cerebellar cortex was used as the reference region for FMISO. FDG-positive was defined as the FDG TNR ≥1.0, and FMISO-positive was defined as FMISO TNR ≥1.3. Hypoxia volume (HV) was defined as the volume of FMISO-positive and metabolic tumor volume in hypoxia (hMTV) was the volume of FMISO/FDG double-positive. The total lesion glycolysis in hypoxia (hTLG) was hMTV × FDG SUVmean. The extent of resection (EOR) involving cytoreduction surgery was volumetric change based on planimetry methods using MRI. These factors were tested for correlation with patient prognosis.

Results

All tumor lesions were FMISO-positive and FDG-positive. Univariate analysis indicated that hMTV, hTLG, and EOR were significantly correlated with PFS (p = 0.007, p = 0.04, and p = 0.01, respectively) and that hMTV, hTLG, and EOR were also significantly correlated with OS (p = 0.0028, p = 0.037, and p = 0.014, respectively). In contrast, none of FDG TNR, FMISO TNR, GTV, HV, patients’ age, or Karnofsky performance scale (KPS) was significantly correlated with PSF or OS. The hMTV and hTLG were found to be independent factors affecting PFS and OS on multivariate analysis.

Conclusions

We introduced hMTV and hTLG using FDG and FMISO PET to define metabolically active hypoxic volume. Univariate and multivariate analyses demonstrated that both hMTV and hTLG are significant predictors for PFS and OS in glioblastoma patients.

Keywords

Anaerobic glycolysis Glioblastoma Fluoromisonidazole Fluorodeoxyglucose Positron emission tomography 

Supplementary material

259_2016_3541_MOESM1_ESM.docx (646 kb)
ESM 1(DOCX 645 kb)

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50. doi:10.1001/jama.2013.280319.CrossRefPubMedGoogle Scholar
  3. 3.
    Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032–42. doi:10.1002/cncr.23678.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol. 2009;2(3):263–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70. doi:10.1007/s00259-011-2037-0.
  6. 6.
    Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res : Off J Am Assoc Cancer Res. 2004;10(24):8177–84. doi:10.1158/1078-0432.CCR-04-1081.CrossRefGoogle Scholar
  7. 7.
    Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, Knisely JP. The interactions of polarographic measurements of oxygen tension and histological grade in human glioma. Cancer J. 2006;12(6):461–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, et al. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3320-x.
  9. 9.
    Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015;45(2):136–50. doi:10.1053/j.semnuclmed.2014.10.001.
  10. 10.
    Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neuro-Oncol. 2009;92(3):317–35. doi:10.1007/s11060-009-9827-2.CrossRefGoogle Scholar
  11. 11.
    Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(9):2623–30. doi:10.1158/1078-0432.CCR-07-4995.
  12. 12.
    Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med: Off Publ Soc Nucl Med. 2009;50(1):36–44. doi:10.2967/jnumed.108.055467.
  13. 13.
    Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502–9. doi:10.1158/0008-5472.CAN-08-3884.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8. doi:10.1007/s00259-014-2776-9.
  15. 15.
    Colavolpe C, Metellus P, Mancini J, et al. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neuro-Oncol. 2012;107(3):527–35. doi:10.1007/s11060-011-0771-6.CrossRefGoogle Scholar
  16. 16.
    Spence AM, Muzi M, Graham MM, O’Sullivan F, Link JM, Lewellen TK, et al. 2-[18F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8(4):971–9.Google Scholar
  17. 17.
    Pardo FS, Aronen HJ, Fitzek M, et al. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res. 2004;24(4):2359–65.PubMedGoogle Scholar
  18. 18.
    Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapp. 1994;2(4):189–210. doi:10.1002/hbm.460020402.
  19. 19.
    Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med: Off Publ Soc Nucl Med. 2004;45(11):1851–9.Google Scholar
  20. 20.
    Yamaguchi S, Kobayashi H, Terasaka S, et al. The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas. Jpn J Clin Oncol. 2012;42(4):270–7. doi:10.1093/jjco/hys016.CrossRefPubMedGoogle Scholar
  21. 21.
    Yamaguchi S, Kobayashi H, Hirata K, Shiga T, Tanaka S, Murata J, et al. Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with 18F-FDG and 11C-methionine: report of two cases. J Neuro-Oncol. 2011;101(2):335–41. doi:10.1007/s11060-010-0262-1.
  22. 22.
    Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, et al. Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 2015;42(7):1071–80. doi:10.1007/s00259-015-3046-1.
  23. 23.
    Yoshikawa K, Kajiwara K, Morioka J, et al. Improvement of functional outcome after radical surgery in glioblastoma patients: the efficacy of a navigation-guided fence-post procedure and neurophysiological monitoring. J Neuro-Oncol. 2006;78(1):91–7. doi:10.1007/s11060-005-9064-2.CrossRefGoogle Scholar
  24. 24.
    Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Therneau T. A package for survival analysis in S. version 2.38. 2015. http://CRAN.R-project.org/package=survival. Accessed 25 Sept 2016.
  26. 26.
    Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. doi:10.3171/2011.2.JNS10998.
  27. 27.
    Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466–74.PubMedGoogle Scholar
  28. 28.
    Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64. doi:10.1227/01.neu.0000318159.21731.cf. discussion 264-6.CrossRefPubMedGoogle Scholar
  30. 30.
    Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8. doi:10.3171/jns.2001.95.2.0190.CrossRefPubMedGoogle Scholar
  31. 31.
    Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol. 2012;3:140. doi:10.3389/fneur.2012.00140.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol : Off J Am Soc Clin Oncol. 2014;32(8):774–82. doi:10.1200/JCO.2013.51.8886.CrossRefGoogle Scholar
  33. 33.
    Gao JL, Chen YG. Natural Compounds Regulate Glycolysis in Hypoxic Tumor Microenvironment. Biomed Res Int. 2015;2015:354143. doi:10.1155/2015/354143.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Pak K, Cheon GJ, Nam HY, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med : Off Publ Soc Nucl Med. 2014;55(6):884–90. doi:10.2967/jnumed.113.133801.CrossRefGoogle Scholar
  35. 35.
    Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med : Off Publ Soc Nucl Med. 2008;49(5):694–9. doi:10.2967/jnumed.107.048082.CrossRefGoogle Scholar
  36. 36.
    Suzuki H, Nishio M, Nakanishi H, Hanai N, Hirakawa H, Kodaira T, et al. Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. Oncol Lett. 2016;12(2):1493–500. doi:10.3892/ol.2016.4765.
  37. 37.
    Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49(3):261–8. doi:10.1016/j.oraloncology.2012.09.005.CrossRefPubMedGoogle Scholar
  38. 38.
    Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med : Off Publ Soc Nucl Med. 2012;53(10):1506–13. doi:10.2967/jnumed.111.101402.
  39. 39.
    Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2013;35(1):15–22. doi:10.1002/hed.22904.
  40. 40.
    Picchio M, Kirienko M, Mapelli P, Dell’Oca I, Villa E, Gallivanone F, et al. Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):21–31. doi:10.1007/s00259-013-2528-2.
  41. 41.
    Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res : Off J Am Assoc Cancer Res. 2012;18(20):5585–94. doi:10.1158/1078-0432.CCR-12-0858.CrossRefGoogle Scholar
  42. 42.
    Groussard C, Morel I, Chevanne M, Monnier M, Cillard J, Delamarche A. Free radical scavenging and antioxidant effects of lactate ion: an in vitro study. J Appl Physiol. 2000;89(1):169–75.PubMedGoogle Scholar
  43. 43.
    Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A. The role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6), E6. doi:10.3171/2014.9.FOCUS14494.CrossRefPubMedGoogle Scholar
  44. 44.
    Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K, et al. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013;85(1):142–7. doi:10.1016/j.ijrobp.2012.03.029.
  45. 45.
    Hatano T, Zhao S, Zhao Y, et al. Biological characteristics of intratumoral [F-18]fluoromisonidazole distribution in a rodent model of glioma. Int J Oncol. 2013;42(3):823–30. doi:10.3892/ijo.2013.1781.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Takuya Toyonaga
    • 1
  • Shigeru Yamaguchi
    • 1
    • 2
  • Kenji Hirata
    • 1
  • Kentaro Kobayashi
    • 1
  • Osamu Manabe
    • 1
  • Shiro Watanabe
    • 1
  • Shunsuke Terasaka
    • 2
  • Hiroyuki Kobayashi
    • 2
  • Naoya Hattori
    • 1
  • Tohru Shiga
    • 1
  • Yuji Kuge
    • 3
  • Shinya Tanaka
    • 4
  • Yoichi M. Ito
    • 5
  • Nagara Tamaki
    • 1
  1. 1.Department of Nuclear MedicineHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Department of NeurosurgeryHokkaido University Graduate School of MedicineSapporoJapan
  3. 3.Central Institute of Isotope ScienceHokkaido UniversitySapporoJapan
  4. 4.Department of Cancer PathologyHokkaido University Graduate School of MedicineSapporoJapan
  5. 5.Department of BiostatisticsHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations